Introduction
Methods
Study population
Data and sample collection
Hormone measurements
Statistical analysis
Results
CGC | NCGC | |||||
---|---|---|---|---|---|---|
Cases/controls (61/61) | Crude ORa (95% CI) | Adjusted ORb (95% CI) | Cases/controls (104/104) | Crude ORa (95% CI) | Adjusted ORb (95% CI) | |
Insulin (pg/mL)c | ||||||
< 243 | 5/5 | Reference | 14/15 | Reference | Reference | |
243–333 | 4/6 | 0.88 (0.21–3.65) | – | 8/15 | 0.61 (0.20–1.91) | 0.98 (0.22–4.47) |
> 333 | 7/5 | 2.72 (0.22–33.0) | – | 23/15 | 1.58 (0.58–4.30) | 1.31 (0.30–5.67) |
P trend | 0.63 | 0.20 | 0.91 | |||
Per 1-SD increase | 1.07 (0.38–2.98) | 1.70 (0.16–18.50) | 1.26 (0.83–1.92) | 1.21 (0.61–2.40) | ||
C-peptide (pmol/L)d | ||||||
< 552 | 19/16 | Reference | Reference | 34/37 | Reference | Reference |
552–968 | 21/22 | 0.79 (0.31–2.02) | 0.99 (0.30–3.26) | 33/33 | 1.09 (0.56–2.14) | 1.03 (0.45–2.33) |
> 968 | 21/23 | 0.75 (0.30–1.90) | 0.66 (0.23–1.91) | 35/32 | 1.20 (0.61–2.36) | 1.28 (0.55–3.01) |
P trend | 0.82 | 0.67 | 0.87 | 0.82 | ||
Per 1-SD increase | 1.11 (0.76–1.62) | 0.99 (0.65–1.53) | 1.02 (0.79–1.32) | 1.03 (0.75–1.43) | ||
IGF-1 (ng/mL) | ||||||
< 82 | 15/18 | Reference | Reference | 28/36 | Reference | Reference |
82–104 | 20/19 | 1.33 (0.52–3.41) | 1.98 (0.59–6.62) | 38/37 | 1.32 (0.68–2.56) | 1.63 (0.75–3.51) |
> 104 | 26/24 | 1.51 (0.49–4.71) | 2.84 (0.64–12.52) | 38/31 | 1.85 (0.82–4.17) | 2.67 (0.97–7.31) |
P trend | 0.76 | 0.37 | 0.33 | 0.15 | ||
Per 1-SD increase | 1.50 (0.95–2.39) | 1.94 (1.03–3.63) | 1.37 (0.97–1.94) | 1.63 (1.05–2.53) | ||
IGFBP-3 (ng/mL) | ||||||
< 1939 | 28/22 | Reference | Reference | 49/33 | Reference | Reference |
1939–2265 | 11/21 | 0.40 (0.15–1.07) | 0.40 (0.11–1.41) | 23/33 | 0.49 (0.25–0.96) | 0.49 (0.23–1.07) |
> 2265 | 22/18 | 0.94 (0.37–2.37) | 1.67 (0.47–5.98) | 32/38 | 0.55 (0.27–1.08) | 0.65 (0.29–1.42) |
P trend | 0.14 | 0.13 | 0.08 | 0.18 | ||
Per 1-SD increase | 0.92 (0.63–1.33) | 1.09 (0.69–1.73) | 0.68 (0.48–0.96) | 0.73 (0.50–1.07) | ||
Adiponectin (ng/mL) | ||||||
< 5057 | 17/18 | Reference | Reference | 44/37 | Reference | Reference |
5057–7023 | 19/18 | 1.15 (0.41–3.22) | 0.92 (0.24–3.51) | 28/36 | 0.62 (0.30–1.26) | 0.83 (0.36–1.92) |
> 7023 | 25/25 | 1.08 (0.44–2.66) | 1.13 (0.37–3.42) | 32/31 | 0.84 (0.41–1.72) | 1.16 (0.47–2.81) |
P trend | 0.97 | 0.93 | 0.41 | 0.76 | ||
Per 1-SD increase | 0.96 (0.69–1.34) | 1.03 (0.68–1.56) | 0.91 (0.68–1.23) | 1.06 (0.73–1.54) | ||
Leptin (pg/mL) | ||||||
< 2142 | 14/13 | Reference | Reference | 25/40 | Reference | Reference |
2142–4105 | 28/24 | 1.07 (0.43–2.68) | 0.83 (0.23–2.98) | 41/31 | 2.43 (1.12–5.24) | 2.99 (1.17–7.64) |
> 4105 | 17/22 | 0.70 (0.25–1.92) | 0.42 (0.09–1.97) | 37/32 | 1.97 (0.96–4.04) | 2.72 (1.01–7.34) |
P trend | 0.60 | 0.47 | 0.06 | 0.06 | ||
Per 1-SD increase | 0.88 (0.62–1.24) | 0.73 (0.42–1.29) | 1.25 (0.94–1.67) | 1.39 (0.91–2.12) | ||
Ghrelin (pg/mL) | ||||||
< 173 | 23/19 | Reference | Reference | 49/36 | Reference | Reference |
173–276 | 14/17 | 0.72 (0.30–1.72) | 0.60 (0.18–2.05) | 33/37 | 0.52 (0.23–1.15) | 0.40 (0.15–1.04) |
> 276 | 24/25 | 0.82 (0.38–1.80) | 0.62
(0.23–1.71) | 22/31 | 0.39 (0.17–0.93) | 0.30 (0.11–0.87) |
P trend | 0.74 | 0.59 | 0.08 | 0.05 | ||
Per 1-SD increase | 0.86 (0.61–1.20) | 0.75 (0.48–1.16) | 0.57 (0.39–0.85) | 0.53 (0.34–0.84) | ||
Androstenedione (pmol/L) | ||||||
< 2291 | 15/16 | Reference | Reference | 25/25 | Reference | Reference |
2291–3203 | 15/12 | 1.70 (0.36–7.91) | 0.97 (0.05–18.41) | 28/29 | 0.97 (0.45–2.11) | 1.16 (0.45–3.04) |
> 3203 | 15/17 | 1.08 (0.27–4.26) | 0.55 (0.04–7.06) | 25/24 | 1.06 (0.44–2.56) | 1.28 (0.36–4.55) |
P trend | 0.71 | 0.79 | 0.98 | 0.92 | ||
Per 1-SD increase | 1.41 (0.80–2.49) | 1.55 (0.67–3.58) | 0.93 (0.64–1.36) | 1.07 (0.62–1.86) | ||
DHEA (pmol/L) | ||||||
< 5540 | 19/18 | Reference | Reference | 25/22 | Reference | Reference |
5540–8496 | 11/12 | 0.84 (0.27–2.65) | 0.30 (0.04–2.17) | 25/29 | 0.63 (0.22–1.80) | 0.82 (0.24–2.77) |
> 8496 | 15/15 | 0.89 (0.24–3.35) | 0.46 (0.05–4.15) | 28/27 | 0.77 (0.27–2.15) | 0.97 (0.27–3.52) |
P trend | 0.96 | 0.49 | 0.68 | 0.91 | ||
Per 1-SD increase | 1.19 (0.71–1.99) | 1.06 (0.50–2.26) | 1.02 (0.68–1.54) | 1.12 (0.63–1.98) | ||
Estrone (pmol/L) | ||||||
< 102 | 15/12 | Reference | Reference | 28/29 | Reference | Reference |
102–136 | 14/17 | 0.61 (0.19–1.91) | 0.56 (0.10–3.12) | 28/23 | 1.22 (0.59–2.51) | 1.46 (0.56–3.78) |
> 136 | 16/16 | 0.74 (0.23–2.37) | 0.69 (0.13–3.61) | 22/26 | 0.81 (0.34–1.94) | 0.65 (0.21–1.99) |
P trend | 0.70 | 0.80 | 0.64 | 0.37 | ||
Per 1-SD increase | 1.10 (0.73–1.65) | 1.10 (0.59–2.05) | 0.99 (0.69–1.43) | 0.79 (0.49–1.27) | ||
Estradiol (pmol/L) | ||||||
< 52.5 | 11/10 | Reference | Reference | 20/30 | Reference | Reference |
52.5–72.7 | 17/19 | 0.80 (0.25–2.55) | 0.30 (0.04–2.23) | 32/23 | 2.49 (1.01–6.15) | 3.09 (0.98–9.73) |
> 72.7 | 17/16 | 0.96 (0.27–3.37) | 0.50 (0.06–4.40) | 26/25 | 1.61 (0.73–3.57) | 1.07 (0.40–2.83) |
P trend | 0.90 | 0.47 | 0.14 | 0.12 | ||
Per 1-SD increase | 1.04 (0.68–1.59) | 0.90 (0.42–1.94) | 1.28 (0.94–1.74) | 1.11 (0.74–1.66) | ||
Free estradiol (pmol/L) | ||||||
< 1.4 | 9/11 | Reference | Reference | 20/30 | Reference | Reference |
1.4–1.8 | 22/16 | 1.63 (0.55–4.79) | 1.89 (0.39–9.12) | 25/25 | 1.50 (0.65–3.48) | 0.99 (0.34–2.92) |
> 1.8 | 14/18 | 0.96 (0.31–2.94) | 0.70 (0.10–4.85) | 33/23 | 2.13 (0.97–4.69) | 1.65 (0.59–4.61) |
P trend | 0.48 | 0.40 | 0.17 | 0.55 | ||
Per 1-SD increase | 0.95 (0.63–1.43) | 0.87 (0.41–1.88) | 1.34 (0.96–1.87) | 1.16 (0.74–1.83) | ||
SHBG (nmol/L)e | ||||||
< 29.4 | 11/17 | Reference | Reference | 29/38 | Reference | Reference |
29.4–46.3 | 24/24 | 1.55 (0.62–3.92) | 1.01 (0.32–3.19) | 41/31 | 1.78 (0.88–3.60) | 1.99 (0.86–4.62) |
> 46.3 | 26/20 | 2.09 (0.77–5.70) | 1.80 (0.51–6.39) | 34/35 | 1.36 (0.63–2.92) | 2.26 (0.75–6.78) |
P trend | 0.35 | 0.54 | 0.27 | 0.22 | ||
Per 1-SD increase | 1.22 (0.82–1.82) | 1.15 (0.69–1.92) | 1.00 (0.74–1.34) | 1.13 (0.77–1.66) | ||
Testosterone (pmol/L) | ||||||
< 11,207 | 13/15 | Reference | Reference | 25/25 | Reference | Reference |
11,207–14,606 | 15/18 | 0.99 (0.40–2.47) | 1.08 (0.28–4.20) | 21/24 | 0.81 (0.34–1.93) | 0.62 (0.18–2.12) |
> 14,606 | 17/12 | 1.70 (0.58–4.98) | 1.23 (0.24–6.40) | 32/29 | 1.13 (0.55–2.34) | 1.13 (0.42–3.03) |
P trend | 0.53 | 0.97 | 0.78 | 0.62 | ||
Per 1-SD increase | 1.25 (0.80–1.94) | 0.94 (0.49–1.80) | 1.07 (0.80–1.44) | 1.13 (0.74–1.74) | ||
Free testosterone (pmol/L) | ||||||
< 205 | 21/19 | Reference | Reference | 18/22 | Reference | Reference |
205–258 | 10/13 | 0.71 (0.26–1.93) | 0.46 (0.10–2.15) | 30/28 | 1.38 (0.58–3.27) | 1.57 (0.51–4.85) |
> 258 | 14/13 | 1.05 (0.34–3.27) | 0.42 (0.06–2.82) | 30/28 | 1.43 (0.56–3.68) | 1.73 (0.50–6.07) |
P trend | 0.77 | 0.50 | 0.72 | 0.66 | ||
Per 1-SD increase | 1.05 (0.68–1.64) | 0.87 (0.45–1.71) | 1.20 (0.81–1.75) | 1.27 (0.74–2.17) | ||
Progesterone (pmol/L) | ||||||
< 122 | 16/15 | Reference | Reference | 27/26 | Reference | Reference |
122–186 | 10/16 | 0.53 (01.6–1.82) | 0.63 (0.09–4.57) | 26/24 | 1.04 (0.48–2.25) | 1.68 (0.61–4.64) |
> 186 | 19/14 | 1.33 (0.41–4.29) | 2.60 (0.31–21.46) | 25/28 | 0.84 (0.37–1.89) | 1.46 (0.46–4.60) |
P trend | 0.31 | 0.25 | 0.86 | 0.60 | ||
Per 1-SD increase | 1.14 (0.75–1.72) | 1.38 (0.68–2.80) | 1.05 (0.72–1.52) | 1.33 (0.77–2.30) |
NCGC | |||
---|---|---|---|
Cases/controls (68/68) | Crude ORa (95% CI) | Adjusted ORb (95% CI) | |
Insulin (pg/mL)c | |||
< 202 | 8/10 | Reference | Reference |
202–295 | 10/13 | 0.93 (0.27–3.24) | 1.38 (0.27–7.09) |
> 295 | 14/9 | 1.77 (0.54–5.81) | 5.20 (0.85–31.85) |
P trend | 0.49 | 0.14 | |
Per 1-SD increase | 1.18 (0.72–1.94) | 2.19 (0.84–5.68) | |
C-peptide (pmol/L)d | |||
< 500 | 16/23 | Reference | Reference |
500–753 | 19/25 | 1.02 (0.43–2.43) | 1.16 (0.37–3.69) |
> 753 | 33/20 | 3.20 (1.17–8.78) | 3.84 (1.02–14.43) |
P trend | 0.05 | 0.08 | |
Per 1-SD increase | 1.90 (1.22–2.95) | 2.17 (1.19–3.97) | |
IGF-1 (ng/mL) | |||
< 66.8 | 27/24 | Reference | Reference |
66.8–84.8 | 27/21 | 1.21 (0.49–2.99) | 1.84 (0.58–5.85) |
> 84.8 | 14/23 | 0.39 (0.13–1.17) | 0.76 (0.19–2.94) |
P trend | 0.13 | 0.39 | |
Per 1-SD increase | 0.72 (0.46–1.14) | 1.01 (0.56–1.81) | |
IGFBP-3 (ng/mL) | |||
< 2175 | 25/22 | Reference | Reference |
2175–2500 | 27/21 | 0.89 (0.32–2.47) | 1.33 (0.38–4.68) |
> 2500 | 16/25 | 0.43 (0.14–1.36) | 0.60 (0.14–2.61) |
P trend | 0.21 | 0.38 | |
Per 1-SD increase | 0.71 (0.47–1.06) | 0.86 (0.51–1.45) | |
Adiponectin (ng/mL) | |||
< 8479 | 21/22 | Reference | Reference |
8479–13,988 | 33/20 | 2.02 (0.80–5.15) | 1.85 (0.57–5.96) |
> 13,988 | 14/26 | 0.61 (0.25–1.50) | 0.60 (0.19–1.89) |
P trend | 0.04 | 0.14 | |
Per 1-SD increase | 0.86 (0.62–1.19) | 0.84 (0.55–1.29) | |
Leptin (pg/mL) | |||
< 6870 | 18/21 | Reference | Reference |
6870–15,472 | 20/21 | 1.14 (0.45–2.85) | 2.03 (0.51–8.01) |
> 15,472 | 30/26 | 1.55 (0.58–4.17) | 3.73 (0.76–18.28) |
P trend | 0.67 | 0.26 | |
Per 1-SD increase | 1.19 (0.80–1.77) | 1.66 (0.88–3.16) | |
Ghrelin (pg/mL) | |||
< 193 | 25/20 | Reference | Reference |
193–345 | 24/22 | 0.87 (0.39–1.96) | 1.03 (0.38–2.83) |
> 345 | 19/26 | 0.59 (0.25–1.36) | 0.52 (0.18–1.52) |
P trend | 0.44 | 0.35 | |
Per 1-SD increase | 0.79 (0.56–1.11) | 0.79 (0.51–1.22) | |
Androstenedione (pmol/L) | |||
< 1378 | 15/15 | Reference | Reference |
1378–2165 | 25/19 | 1.07 (0.38–2.99) | 1.01 (0.28–3.63) |
> 2165 | 13/19 | 0.63 (0.19–2.07) | 1.20 (0.23–6.28) |
P trend | 0.61 | 0.97 | |
Per 1-SD increase | 0.88 (0.55–1.39) | 1.21 (0.65–2.24) | |
DHEA (pmol/L) | |||
< 4024 | 16/18 | Reference | Reference |
4024–8310 | 24/16 | 1.69 (0.58–4.87) | 2.26 (0.58–8.86) |
> 8310 | 13/19 | 0.72 (0.21–2.47) | 1.54 (0.29–8.30) |
P trend | 0.25 | 0.48 | |
Per 1-SD increase | 0.81 (0.50–1.31) | 1.07 (0.58–1.98) | |
Estrone (pmol/L) | |||
< 53.6 | 16/17 | Reference | Reference |
53.6–83.2 | 22/17 | 1.35 (0.54–3.36) | 2.20 (0.63–7.67) |
> 83.2 | 15/19 | 0.79 (0.28–2.18) | 1.75 (0.41–7.56) |
P trend | 0.55 | 0.47 | |
Per 1-SD increase | 1.12 (0.74–1.70) | 1.49 (0.88–2.52) | |
Estradiol (pmol/L) | |||
< 9.2 | 14/16 | Reference | Reference |
9.2–16.1 | 20/14 | 1.82 (0.64–5.13) | 6.45 (1.09–38.40) |
> 16.1 | 13/17 | 0.74 (0.25–2.18) | 2.47 (0.29–21.04) |
P trend | 0.33 | 0.12 | |
Per 1-SD increase | 0.99 (0.64–1.53) | 1.12 (0.59–2.15) | |
Free estradiol (pmol/L) | |||
< 0.2 | 16/13 | Reference | Reference |
0.2–0.4 | 17/17 | 0.83 (0.31–2.25) | 1.82 (0.41–8.00) |
> 0.4 | 14/17 | 0.67 (0.24–1.87) | 1.36 (0.23–8.26) |
P trend | 0.74 | 0.73 | |
Per 1-SD increase | 1.03 (0.67–1.59) | 1.13 (0.59–2.16) | |
SHBG (nmol/L)e | |||
< 44.6 | 23/21 | Reference | Reference |
44.6–63.7 | 27/25 | 0.97 (0.41–2.33) | 1.44 (0.45–4.62) |
> 63.7 | 18/22 | 0.75 (0.31–1.81) | 0.91 (0.26–3.15) |
P trend | 0.77 | 0.67 | |
Per 1-SD increase | 0.82 (0.57–1.17) | 0.81 (0.48–1.36) | |
Testosterone (pmol/L) | |||
< 454 | 21/16 | Reference | Reference |
454–697 | 18/18 | 0.78 (0.30–2.00) | 0.86 (0.26–2.82) |
> 697 | 14/19 | 0.58 (0.23–1.47) | 0.49 (0.13–1.94) |
P trend | 0.51 | 0.59 | |
Per 1-SD increase | 0.91 (0.62–1.32) | 1.01 (0.62–1.65) | |
Free testosterone (pmol/L) | |||
< 5.4 | 16/16 | Reference | Reference |
5.4–8.5 | 21/18 | 1.24 (0.40–3.85) | 2.05 (0.43–9.73) |
> 8.5 | 16/19 | 0.85 (0.29–2.48) | 1.20 (0.23–6.30) |
P trend | 0.76 | 0.62 | |
Per 1-SD increase | 0.97 (0.66–1.43) | 1.07 (0.64–1.78) | |
Progesterone (pmol/L) | |||
< 71.5 | 15/16 | Reference | Reference |
71.5–101 | 19/20 | 1.02 (0.38–2.79) | 0.83 (0.23–3.06) |
> 101 | 19/17 | 1.22 (0.44–3.40) | 1.41 (0.39–5.11) |
P trend | 0.91 | 0.71 | |
Per 1-SD increase | 1.11 (0.77–1.61) | 1.12 (0.67–1.88) |
CGC | NCGC | |||||
---|---|---|---|---|---|---|
Cases/controls (100/100) | Crude ORa (95% CI) | Adjusted ORb (95% CI) | Cases/Controls (65/65) | Crude ORa (95% CI) | Adjusted ORb (95% CI) | |
Insulin (pg/mL) | ||||||
< 184 | 35/41 | Reference | Reference | 18/12 | Reference | Reference |
184–325 | 34/33 | 1.21 (0.63–2.31) | 0.95 (0.46–1.96) | 28/21 | 0.91 (0.38–2.22) | 0.90 (0.31–2.61) |
> 325 | 30/25 | 1.39 (0.70–2.74) | 0.71 (0.29–1.74) | 17/30 | 0.41 (0.16–1.03) | 0.30 (0.08–1.12) |
P trend | 0.64 | 0.72 | 0.09 | 0.08 | ||
Per 1-SD increase | 1.10 (0.85–1.42) | 0.85 (0.60–1.20) | 0.63 (0.41–0.97) | 0.45 (0.22–0.91) | ||
IGF-1 (ng/mL) | ||||||
< 84.3 | 34/32 | Reference | Reference | 22/21 | Reference | Reference |
84.3–108 | 41/31 | 1.30 (0.69–2.46) | 1.19 (0.59–2.37) | 21/23 | 0.86 (0.36–2.08) | 0.90 (0.35–2.29) |
> 108 | 24/36 | 0.58 (0.28–1.19) | 0.60 (0.27–1.30) | 19/18 | 1.01 (0.39–2.58) | 1.10 (0.40–3.02) |
P trend | 0.12 | 0.25 | 0.93 | 0.93 | ||
Per 1-SD increase | 0.85 (0.64–1.13) | 0.83 (0.61–1.14) | 1.09 (0.73–1.64) | 1.11 (0.72–1.73) | ||
IGFBP-3 (ng/mL) | ||||||
< 1642 | 42/38 | Reference | Reference | 15/14 | Reference | Reference |
1642–2084 | 26/31 | 0.79 (0.41–1.49) | 1.09 (0.53–2.22) | 23/21 | 1.01 (0.40–2.56) | 1.08 (0.40–2.91) |
> 2084 | 29/28 | 0.94 (0.48–1.83) | 1.14 (0.53–2.44) | 23/26 | 0.79 (0.29–2.13) | 0.87 (0.30–2.54) |
P trend | 0.75 | 0.17 | 0.84 | 0.90 | ||
Per 1-SD increase | 1.01 (0.76–1.33) | 1.10 (0.80–1.51) | 1.07 (0.69–1.66) | 1.14 (0.71–1.83) | ||
Adiponectin (ng/mL) | ||||||
< 6065 | 45/23 | Reference | Reference | 21/29 | Reference | Reference |
6065–8855 | 27/41 | 0.41 (0.21–0.79) | 0.41 (0.20–0.87) | 24/14 | 2.88 (1.05–7.96) | 2.58 (0.86–7.72) |
> 8855 | 27/35 | 0.44 (0.21–0.89) | 0.56 (0.25–1.25) | 17/19 | 1.52 (0.60–3.85) | 1.42 (0.48–4.14) |
P trend | 0.02 | 0.06 | 0.12 | 0.22 | ||
Per 1-SD increase | 0.73 (0.55–0.96) | 0.85 (0.62–1.17) | 1.11 (0.78–1.57) | 1.06 (0.72–1.57) | ||
Leptin (pg/mL) | ||||||
< 1398 | 22/37 | Reference | Reference | 17/17 | Reference | Reference |
1398–3955 | 51/34 | 2.53 (1.24–5.16) | 1.51 (0.66–3.43) | 23/20 | 1.15 (0.51–2.61) | 1.35 (0.53–3.42) |
> 3955 | 26/28 | 1.62 (0.73–3.57) | 0.67 (0.23–2.02) | 23/26 | 0.87 (0.38–1.96) | 1.10 (0.33–3.65) |
P trend | 0.04 | 0.13 | 0.81 | 0.81 | ||
Per 1-SD increase | 1.21 (0.89–1.63) | 0.83 (0.53–1.29) | 0.75 (0.53–1.07) | 0.56 (0.29–1.09) | ||
Ghrelin (pg/mL) | ||||||
< 596 | 51/3 | Reference | Reference | 45/21 | Reference | Reference |
596–833 | 23/3 | 1.89 (0.08–44.94) | - | 13/22 | 0.37 (0.16–0.88) | 0.29 (0.11–0.81) |
> 833 | 10/4 | 0.53 (0.02–12.54) | - | 7/22 | < 0.001 (< 0.001- > 999) | - < 0.001 (< 0.001- > 999) |
P trend | 0.60 | 0.08 | 0.06 | |||
Per 1-SD increase | 0.45 (0.10–2.08) | 0.27 (0.14–0.53) | 0.22 (0.10–0.50) | |||
Androstenedione (pmol/L) | ||||||
< 3702 | 23/23 | Reference | Reference | 30/31 | Reference | Reference |
3702–5084 | 38/34 | 1.17 (0.54–2.55) | 1.23 (0.51–2.94) | 25/21 | 1.26 (0.53–2.97) | 1.31 (0.51–3.36) |
> 5084 | 39/43 | 0.92 (0.47–1.82) | 0.95 (0.43–2.11) | 10/13 | 0.79 (0.27–2.29) | 0.71 (0.21–2.37) |
P trend | 0.79 | 0.79 | 0.67 | 0.58 | ||
Per 1-SD increase | 0.99 (0.74–1.33) | 1.00 (0.71–1.40) | 1.04 (0.74–1.48) | 0.99 (0.69–1.44) | ||
Androsterone (pmol/L) | ||||||
< 755 | 24/28 | Reference | Reference | NM | NM | |
755–1008 | 26/28 | 1.13 (0.49–2.57) | 1.24 (0.49–3.15) | |||
> 1008 | 34/28 | 1.50 (0.67–3.36) | 2.15 (0.82–5.68) | |||
P trend | 0.59 | 0.26 | ||||
Per 1-SD increase | 1.17 (0.84–1.63) | 1.25 (0.86–1.81) | ||||
DHEA (pmol/L) | ||||||
< 7722 | 33/23 | Reference | Reference | 28/28 | Reference | Reference |
7722–11,836 | 37/34 | 0.72 (0.35–1.46) | 0.95 (0.43–2.10) | 21/18 | 1.11 (0.51–2.42) | 1.07 (0.46–2.52) |
> 11,836 | 29/42 | 0.43 (0.20–0.95) | 0.51 (0.22–1.21) | 7/10 | 0.61 (0.17–2.22) | 0.68 (0.16–2.89) |
P trend | 0.10 | 0.03 | 0.65 | 0.82 | ||
Per 1-SD increase | 0.73 (0.53–1.00) | 0.75 (0.53–1.07) | 0.78 (0.52–1.17) | 0.73 (0.45–1.17) | ||
Estrone (pmol/L) | ||||||
< 124 | 41/38 | Reference | Reference | 23/17 | Reference | Reference |
124–161 | 22/28 | 0.72 (0.35–1.49) | 0.57 (0.25–1.31) | 22/26 | 0.58 (0.23–1.48) | 0.55 (0.20–1.54) |
> 161 | 37/34 | 1.01 (0.53–1.93) | 0.65 (0.31–1.38) | 20/22 | 0.69 (0.31–1.55) | 0.73 (0.31–1.73) |
P trend | 0.61 | 0.36 | 0.49 | 0.52 | ||
Per 1-SD increase | 0.99 (0.72–1.36) | 0.85 (0.59–1.20) | 0.90 (0.67–1.20) | 0.91 (0.66–1.24) | ||
Estradiol (pmol/L) | ||||||
< 66.2 | 30/27 | Reference | Reference | 30/28 | Reference | Reference |
66.2–92.3 | 33/34 | 0.84 (0.38–1.86) | 0.67 (0.27–1.66) | 25/20 | 1.30 (0.53–3.19) | 1.15 (0.44–3.03) |
> 92.3 | 37/39 | 0.84 (0.42–1.68) | 0.62 (0.29–1.34) | 10/17 | 0.62 (0.26–1.48) | 0.66 (0.26–1.70) |
P trend | 0.88 | 0.47 | 0.33 | 0.57 | ||
Per 1-SD increase | 1.00 (0.75–1.34) | 0.89 (0.65–1.23) | 0.91 (0.67–1.23) | 0.91 (0.66–1.26) | ||
Free estradiol (pmol/L) | ||||||
< 1.4 | 27/30 | Reference | Reference | 26/25 | Reference | Reference |
1.4–1.9 | 41/35 | 1.37 (0.64–2.95) | 1.09 (0.47–2.54) | 22/19 | 1.12 (0.50–2.50) | 1.25 (0.53–2.95) |
> 1.9 | 32/35 | 1.07 (0.52–2.19) | 0.69 (0.30–1.57) | 17/21 | 0.79 (0.35–1.79) | 0.85 (0.34–2.13) |
P trend | 0.66 | 0.42 | 0.73 | 0.74 | ||
Per 1-SD increase | 1.05 (0.78–1.40) | 0.83 (0.60–1.17) | 0.93 (0.69–1.25) | 0.94 (0.68–1.29) | ||
SHBG (nmol/L)c | ||||||
< 49.0 | 31/24 | Reference | Reference | 31/31 | Reference | Reference |
49.0–75.5 | 33/35 | 0.72 (0.33–1.56) | 0.89 (0.35–2.25) | 21/19 | 1.08 (0.46–2.52) | 0.87 (0.28–2.73) |
> 75.5 | 36/41 | 0.65 (0.31–1.38) | 0.99 (0.40–2.49) | 13/15 | 0.84 (0.29–2.43) | 0.72 (0.20–2.62) |
P trend | 0.51 | 0.96 | 0.88 | 0.88 | ||
Per 1-SD increase | 0.91 (0.67–1.25) | 1.13 (0.75–1.70) | 0.96 (0.66–1.40) | 0.85 (0.52–1.40) | ||
Testosterone (pmol/L) | ||||||
< 15,075 | 25/20 | Reference | Reference | 26/32 | Reference | Reference |
15,075–22,877 | 38/35 | 0.89 (0.43–1.84) | 1.33 (0.56–3.15) | 26/17 | 1.70 (0.78–3.72) | 1.79 (0.74–4.34) |
> 22,877 | 36/44 | 0.65 (0.31–1.35) | 1.06 (0.43–2.63) | 6/9 | 0.90 (0.26–3.11) | 0.86 (0.22–3.35) |
P trend | 0.46 | 0.75 | 0.30 | 0.30 | ||
Per 1-SD increase | 0.93 (0.70–1.24) | 1.02 (0.73–1.43) | 1.25 (0.82–1.90) | 1.19 (0.73–1.93) | ||
Free testosterone (pmol/L) | ||||||
< 215 | 31/26 | Reference | Reference | 25/25 | Reference | Reference |
215–282 | 34/31 | 0.95 (0.47–1.91) | 1.00 (0.47–2.14) | 23/23 | 1.00 (0.46–2.20) | 0.81 (0.33–2.03) |
> 282 | 34/42 | 0.65 (0.32–1.33) | 0.65 (0.30–1.42) | 10/10 | 1.00 (0.34–2.92) | 1.29 (0.36–4.65) |
P trend | 0.45 | 0.47 | 1.00 | 0.81 | ||
Per 1-SD increase | 0.97 (0.72–1.31) | 0.94 (0.68–1.30) | 1.15 (0.81–1.64) | 1.13 (0.75–1.71) | ||
Dihydrotestosterone (pmol/L) | ||||||
< 1295 | 33/33 | Reference | Reference | NM | NM | |
1295–1797 | 28/32 | 0.88 (0.44–1.79) | 1.29 (0.55–3.05) | |||
> 1797 | 38/34 | 1.11 (0.56–2.18) | 1.72 (0.72–4.06) | |||
P trend | 0.80 | 0.45 | ||||
Per 1-SD increase | 1.09 (0.82–1.45) | 1.33 (0.91–1.95) | ||||
Progesterone (pmol/L) | ||||||
< 146 | NM | NM | 23/21 | Reference | Reference | |
146–223 | 27/22 | 1.08 (0.48–2.47) | 1.15 (0.44–2.97) | |||
> 223 | 15/22 | 0.64 (0.26–1.56) | 0.72 (0.26–1.97) | |||
P trend | 0.43 | 0.57 | ||||
Per 1-SD increase | 0.92 (0.65–1.30) | 0.94 (0.64–1.38) |
CGC | NCGC | |||||
---|---|---|---|---|---|---|
Cases/controls (161/161) | Crude ORa (95% CI) | Adjusted ORb (95% CI) | Cases/controls (169/169) | Crude ORa (95% CI) | Adjusted ORb (95% CI) | |
Insulin (pg/mL) | ||||||
< 204 | 48/44 | Reference | Reference | 31/29 | Reference | Reference |
204–328 | 30/43 | 0.64 (0.33–1.23) | 0.51 (0.24–1.06) | 38/33 | 1.12 (0.58–2.17) | 1.20 (0.56–2.61) |
> 328 | 37/28 | 1.17 (0.60–2.29) | 0.65 (0.27–1.57) | 39/46 | 0.81 (0.43–1.51) | 0.72 (0.31–1.66) |
P trend | 0.18 | 0.20 | 0.58 | 0.37 | ||
Per 1-SD increase | 1.09 (0.85–1.40) | 0.91 (0.68–1.23) | 0.87 (0.64–1.17) | 0.75 (0.49–1.17) | ||
IGF-1 (ng/mL) | ||||||
< 82.3 | 49/47 | Reference | Reference | 48/59 | Reference | Reference |
82.3–106 | 62/52 | 1.13 (0.67–1.90) | 1.15 (0.66–1.99) | 59/59 | 1.29 (0.73–2.27) | 1.38 (0.75–2.53) |
> 106 | 49/61 | 0.71 (0.39–1.28) | 0.63 (0.34–1.19) | 59/48 | 1.76 (0.93–3.32) | 1.84 (0.91–3.75) |
P trend | 0.27 | 0.15 | 0.22 | 0.23 | ||
Per 1-SD increase | 1.01 (0.80–1.28) | 0.98 (0.77–1.25) | 1.26 (0.97–1.63) | 1.27 (0.95–1.70) | ||
IGFBP-3 (ng/mL) | ||||||
< 1781 | 72/65 | Reference | Reference | 52/41 | Reference | Reference |
1781–2201 | 45/54 | 0.73 (0.42–1.27) | 0.80 (0.45–1.42) | 57/55 | 0.79 (0.45–1.40) | 0.85 (0.46–1.58) |
> 2201 | 41/39 | 0.91 (0.50–1.66) | 0.78 (0.41–1.50) | 56/69 | 0.60 (0.33–1.07) | 0.59 (0.31–1.12) |
P trend | 0.52 | 0.67 | 0.22 | 0.25 | ||
Per 1-SD increase | 0.98 (0.78–1.22) | 0.96 (0.75–1.21) | 0.81 (0.62–1.06) | 0.82 (0.61–1.10) | ||
Adiponectin (ng/mL) | ||||||
< 5457 | 55/34 | Reference | Reference | 69/74 | Reference | Reference |
5457–7760 | 44/59 | 0.47 (0.27–0.84) | 0.48 (0.27–0.88) | 46/49 | 1.04 (0.61–1.77) | 1.18 (0.65–2.16) |
> 7760 | 61/67 | 0.56 (0.32–0.98) | 0.64 (0.35–1.17) | 51/43 | 1.32 (0.75–2.32) | 1.54 (0.82–2.89) |
P trend | 0.03 | 0.06 | 0.60 | 0.40 | ||
Per 1-SD increase | 0.81 (0.66–1.01) | 0.85 (0.67–1.09) | 0.99 (0.79–1.24) | 1.05 (0.81–1.36) | ||
Leptin (pg/mL) | ||||||
< 1924 | 45/57 | Reference | Reference | 48/50 | Reference | Reference |
1924–4051 | 71/50 | 1.85 (1.06–3.23) | 1.54 (0.82–2.87) | 58/58 | 1.04 (0.61–1.79) | 1.00 (0.55–1.84) |
> 4051 | 42/51 | 1.08 (0.60–1.94) | 0.60 (0.27–1.33) | 60/58 | 1.08 (0.64–1.82) | 0.99 (0.49–2.05) |
P trend | 0.06 | 0.01 | 0.97 | 1.00 | ||
Per 1-SD increase | 1.07 (0.86–1.34) | 0.86 (0.62–1.19) | 0.99 (0.80–1.24) | 0.90 (0.64–1.26) | ||
Ghrelin (pg/mL) | ||||||
< 224 | 28/21 | Reference | Reference | 70/57 | Reference | Reference |
224–451 | 47/35 | 0.67 (0.33–1.39) | 0.67 (0.29–1.51) | 54/46 | 0.73 (0.40–1.36) | 0.51 (0.25–1.07) |
> 451 | 70/15 | 0.88 (0.29–2.64) | 0.54 (0.13–2.29) | 45/66 | 0.24 (0.10–0.56) | 0.14 (0.05–0.41) |
P trend | 0.55 | 0.53 | 0.003 | 0.002 | ||
Per 1-SD increase | 0.89 (0.60–1.34) | 0.75 (0.46–1.25) | 0.43 (0.29–0.63) | 0.27 (0.16–0.47) | ||
Androstenedione (pmol/L) | ||||||
< 2906 | 30/36 | Reference | Reference | 61/60 | Reference | Reference |
2906–4460 | 56/42 | 1.63 (0.81–3.28) | 1.54 (0.70–3.38) | 52/53 | 0.96 (0.53–1.73) | 1.03 (0.53–2.00) |
> 4460 | 59/67 | 1.10 (0.52–2.31) | 1.06 (0.47–2.41) | 30/30 | 0.97 (0.46–2.03) | 0.88 (0.38–2.00) |
P trend | 0.23 | 0.35 | 0.99 | 0.90 | ||
Per 1-SD increase | 1.09 (0.81–1.46) | 1.12 (0.80–1.56) | 0.98 (0.73–1.32) | 0.99 (0.72–1.37) | ||
DHEA (pmol/L) | ||||||
6593 | 46/38 | Reference | Reference | 55/53 | Reference | Reference |
6593–10,997 | 55/44 | 0.90 (0.48–1.70) | 0.76 (0.37–1.55) | 52/49 | 1.03 (0.58–1.85) | 0.82 (0.43–1.58) |
> 10,997 | 43/62 | 0.50 (0.25–0.98) | 0.45 (0.21–0.95) | 27/32 | 0.80 (0.40–1.60) | 0.56 (0.25–1.30) |
P trend | 0.06 | 0.07 | 0.75 | 0.41 | ||
Per 1-SD increase | 0.85 (0.65–1.11) | 0.84 (0.62–1.13) | 0.90 (0.67–1.20) | 0.82 (0.58–1.15) | ||
Estrone (pmol/L) | ||||||
< 110 | 41/45 | Reference | Reference | 53/51 | Reference | Reference |
110–150 | 49/52 | 1.07 (0.59–1.93) | 1.00 (0.54–1.85) | 48/44 | 1.04 (0.58–1.88) | 0.94 (0.48–1.86) |
> 150 | 55/48 | 1.30 (0.70–2.42) | 1.12 (0.58–2.16) | 42/48 | 0.82 (0.45–1.51) | 0.82 (0.42–1.62) |
P trend | 0.66 | 0.91 | 0.72 | 0.85 | ||
Per 1-SD increase | 1.03 (0.80–1.33) | 0.96 (0.73–1.25) | 0.93 (0.73–1.18) | 0.90 (0.69–1.17) | ||
Estradiol (pmol/L) | ||||||
< 61.4 | 37/36 | Reference | Reference | 60/60 | Reference | Reference |
61.4–82.7 | 47/52 | 0.88 (0.47–1.64) | 0.83 (0.43–1.61) | 47/44 | 1.08 (0.60–1.96) | 1.08 (0.56–2.07) |
> 82.7 | 61/57 | 1.03 (0.57–1.87) | 0.89 (0.48–1.67) | 36/39 | 0.93 (0.52–1.65) | 0.92 (0.48–1.74) |
P trend | 0.82 | 0.86 | 0.89 | 0.90 | ||
Per 1-SD increase | 1.01 (0.80–1.29) | 0.95 (0.73–1.22) | 1.07 (0.86–1.33) | 1.02 (0.80–1.31) | ||
Free estradiol (pmol/L) | ||||||
< 1.4 | 39/40 | Reference | Reference | 45/56 | Reference | Reference |
1.4–1.9 | 61/52 | 1.20 (0.65–2.22) | 1.08 (0.56–2.09) | 51/43 | 1.50 (0.83–2.70) | 1.31 (0.69–2.46) |
> 1.9 | 45/53 | 0.91 (0.49–1.66) | 0.69 (0.35–1.36) | 47/44 | 1.30
(0.74–2.30) | 1.22 (0.64–2.33) |
P trend | 0.54 | 0.27 | 0.37 | 0.69 | ||
Per 1-SD increase | 1.02 (0.81–1.28) | 0.90 (0.69–1.17) | 1.09 (0.88–1.35) | 1.06 (0.83–1.34) | ||
SHBG (nmol/L)c | ||||||
< 37.6 | 36/34 | Reference | Reference | 69/76 | Reference | Reference |
37.6–59.5 | 55/61 | 0.86 (0.46–1.60) | 0.86 (0.43–1.70) | 62/48 | 1.42 (0.84–2.42) | 1.51 (0.83–2.74) |
> 59.5 | 70/66 | 1.02 (0.51–2.02) | 1.22 (0.56–2.68) | 38/45 | 0.96 (0.52–1.77) | 0.98 (0.48–1.98) |
P trend | 0.78 | 0.50 | 0.28 | 0.25 | ||
Per 1-SD increase | 1.02 (0.78–1.33) | 1.10 (0.81–1.50) | 0.98 (0.75–1.28) | 0.97 (0.72–1.31) | ||
Testosterone (pmol/L) | ||||||
< 12,637 | 34/33 | Reference | Reference | 50/60 | Reference | Reference |
12,637–18,218 | 42/46 | 0.90 (0.49–1.67) | 0.97 (0.48–1.97) | 54/48 | 1.31 (0.78–2.19) | 1.24 (0.70–2.21) |
> 18,218 | 68/65 | 1.04 (0.54–2.01) | 1.19 (0.55–2.56) | 32/28 | 1.36 (0.72–2.58) | 1.28 (0.62–2.63) |
P trend | 0.88 | 0.81 | 0.49 | 0.08 | ||
Per 1-SD increase | 0.99 (0.78–1.26) | 1.05 (0.80–1.37) | 1.17 (0.88–1.56) | 1.17 (0.85–1.62) | ||
Free testosterone (pmol/L) | ||||||
< 209 | 51/46 | Reference | Reference | 41/47 | Reference | Reference |
209–267 | 44/41 | 0.96 (0.54–1.69) | 0.97 (0.51–1.83) | 55/52 | 1.25(0.69–2.25) | 1.27 (0.65–2.49) |
> 267 | 49/57 | 0.74 (0.41–1.34) | 0.76 (0.39–1.46) | 40/37 | 1.32 (0.69–2.54) | 1.62 (0.76–3.43) |
P trend | 0.57 | 0.65 | 0.66 | 0.45 | ||
Per 1-SD increase | 0.99 (0.79–1.25) | 0.99 (0.77–1.27) | 1.18 (0.90–1.54) | 1.20 (0.90–1.59) | ||
Progesterone (pmol/L) | ||||||
< 130 | NM | NM | 47/47 | Reference | Reference | |
130–202 | 54/47 | 1.12 (0.64–1.97) | 1.21
(0.64–2.27) | |||
> 202 | 42/49 | 0.85 (0.46–1.57) | 0.97 (0.48–1.95) | |||
P trend | 0.62 | 0.73 | ||||
Per 1-SD increase | 0.98 (0.77–1.25) | 1.01 (0.76–1.33) |
CGC | NCGC | |||||
---|---|---|---|---|---|---|
Cases (N = 113) | Crude HRa (95% CI) | Adjusted HRb (95% CI) | Cases (N = 57) | Crude HRa (95% CI) | Adjusted HRb (95% CI) | |
Glucose (mmol/L) | ||||||
< 4.7 | 30 | Reference | Reference | 15 | Reference | Reference |
4.7–5.2 | 29 | 0.94 (0.55–1.62) | 0.97 (0.56–1.67) | 16 | 1.12 (0.54–2.33) | 1.13 (0.54–2.36) |
> 5.2 | 39 | 1.09 (0.65–1.82) | 1.07 (0.63–1.80) | 17 | 1.03 (0.50–2.13) | 1.07 (0.51–2.24) |
P trend | 0.85 | 0.93 | 0.95 | 0.95 | ||
Per 1-SD increase | 1.17 (0.99–1.38) | 1.13 (0.95–1.34) | 1.03 (0.79–1.35) | 1.06 (0.80–1.39) | ||
HbA1c (mmol/mol) | ||||||
< 33.6 | 28 | Reference | Reference | 16 | Reference | Reference |
33.6–37.0 | 26 | 0.86 (0.49–1.51) | 0.77 (0.43–1.37) | 13 | 0.83 (0.39–1.77) | 0.86 (0.40–1.85) |
> 37.0 | 49 | 1.27 (0.76–2.11) | 0.99 (0.59–1.68) | 25 | 1.19 (0.60–2.33) | 1.24 (0.62–2.49) |
P trend | 0.29 | 0.57 | 0.58 | 0.57 | ||
Per 1-SD increase | 1.14 (0.94–1.37) | 1.04 (0.85–1.27) | 1.16 (0.93–1.46) | 1.19 (0.95–1.50) | ||
CRP (mg/L) | ||||||
< 0.8 | 22 | Reference | Reference | 13 | Reference | Reference |
0.8–1.9 | 40 | 1.42 (0.82–2.45) | 1.15 (0.66–2.00) | 16 | 1.17 (0.55–2.50) | 1.22 (0.57–2.63) |
> 1.9 | 44 | 1.60 (0.94–2.72) | 1.10 (0.63–1.94) | 24 | 1.48 (0.73–3.03) | 1.58 (0.74–3.36) |
P trend | 0.23 | 0.89 | 0.53 | 0.47 | ||
Per 1-SD increase | 1.25 (1.03–1.53) | 1.10 (0.88–1.37) | 1.21 (0.92–1.59) | 1.23 (0.93–1.64) | ||
IGF-1 (nmol/L) | ||||||
< 19.6 | 44 | Reference | Reference | 27 | Reference | Reference |
19.6–23.9 | 31 | 0.87 (0.53–1.43) | 0.93 (0.57–1.52) | 15 | 0.70 (0.37–1.33) | 0.69 (0.36–1.32) |
> 23.9 | 31 | 0.99 (0.60–1.62) | 1.06 (0.64–1.75) | 11 | 0.50 (0.23–1.07) | 0.50 (0.23–1.08) |
P trend | 0.85 | 0.89 | 0.18 | 0.17 | ||
Per 1-SD increase | 1.00 (0.82–1.22) | 1.04 (0.85–1.27) | 0.77 (0.60–1.00) | 0.77 (0.59–1.00) | ||
SHBG (nmol/L) | ||||||
< 30.9 | 19 | Reference | Reference | 9 | Reference | Reference |
30.9–43.7 | 34 | 1.42 (0.79–2.55) | 1.68 (0.92–3.06) | 13 | 1.13 (0.47–2.71) | 1.11 (0.46–2.66) |
> 43.7 | 46 | 1.43 (0.81–2.55) | 1.90 (1.04–3.47) | 26 | 1.95 (0.89–4.26) | 1.89 (0.84–4.27) |
P trend | 0.41 | 0.11 | 0.14 | 0.18 | ||
Per 1-SD increase | 1.16 (0.92–1.45) | 1.29 (1.02–1.64) | 1.38 (1.01–1.89) | 1.36 (0.98–1.90) | ||
Testosterone (nmol/L) | ||||||
< 10.2 | 38 | Reference | Reference | 16 | Reference | Reference |
10.2–13.2 | 32 | 0.83 (0.50–1.37) | 0.99 (0.59–1.65) | 11 | 0.59 (0.26–1.33) | 0.61 (0.27–1.39) |
> 13.2 | 37 | 1.00 (0.62–1.62) | 1.28 (0.77–2.13) | 25 | 1.55 (0.82–2.92) | 1.58 (0.81–3.11) |
P trend | 0.70 | 0.55 | 0.04 | 0.05 | ||
Per 1-SD increase | 0.97 (0.79–1.19) | 1.08 (0.87–1.35) | 0.94 (0.72–1.23) | 0.91 (0.69–1.22) | ||
Free testosterone (pmol/L) | ||||||
< 181 | 48 | Reference | Reference | 19 | Reference | Reference |
181–227 | 27 | 0.68 (0.42–1.12) | 0.73 (0.44–1.20) | 20 | 1.39 (0.71–2.70) | 1.37 (0.70–2.68) |
> 227 | 23 | 0.73 (0.42–1.27) | 0.82 (0.47–1.45) | 8 | 0.72 (0.31–1.71) | 0.73 (0.30–1.73) |
P trend | 0.26 | 0.45 | 0.28 | 0.30 | ||
Per 1-SD increase | 0.85 (0.70–1.03) | 0.90 (0.73–1.10) | 0.73 (0.58–0.91) | 0.71 (0.57–0.89) |
CGC | NCGC | |||||
---|---|---|---|---|---|---|
Cases (N = 24) | Crude HRa (95% CI) | Adjusted HRb (95% CI) | Cases (N = 35) | Crude HRa (95% CI) | Adjusted HRb (95% CI) | |
Glucose (mmol/L) | ||||||
< 4.7 | 7 | Reference | Reference | 6 | Reference | Reference |
4.7–5.1 | 6 | 1.19 (0.37–3.83) | 1.19 (0.37–3.86) | 14 | 2.06 (0.77–5.52) | 2.10 (0.78–5.65) |
> 5.1 | 6 | 0.97 (0.28–3.39) | 1.03 (0.29–3.64) | 13 | 1.91 (0.72–5.12) | 1.89 (0.70–5.10) |
P trend | 0.94 | 0.95 | 0.33 | 0.32 | ||
Per 1-SD increase | 1.02 (0.63–1.66) | 1.02 (0.63–1.66) | 1.21 (0.97–1.52) | 1.19 (0.95–1.51) | ||
HbA1c (mmol/mol) | ||||||
< 33.5 | 7 | Reference | Reference | 8 | Reference | Reference |
33.5–36.7 | 11 | 1.15 (0.40–3.24) | 1.12 (0.39–3.20) | 12 | 0.93 (0.37–2.33) | 0.91 (0.36–2.28) |
> 36.7 | 6 | 0.59 (0.18–1.90) | 0.54 (0.16–1.78) | 15 | 0.96 (0.39–2.36) | 0.87 (0.35–2.16) |
P trend | 0.44 | 0.37 | 0.99 | 0.95 | ||
Per 1-SD increase | 0.81 (0.50–1.32) | 0.79 (0.48–1.30) | 1.13 (0.86–1.49) | 1.11 (0.83–1.50) | ||
CRP (mg/L) | ||||||
< 0.8 | 9 | Reference | Reference | 7 | Reference | Reference |
0.8–2.2 | 7 | 0.75 (0.26–2.17) | 0.74 (0.25–2.19) | 15 | 1.61 (0.65–4.01) | 1.53 (0.60–3.90) |
> 2.2 | 8 | 0.77 (0.27–2.17) | 0.69 (0.21–2.21) | 13 | 1.30 (0.51–3.34) | 1.24 (0.44–3.48) |
P trend | 0.84 | 0.80 | 0.59 | 0.65 | ||
Per 1-SD increase | 0.93 (0.59–1.45) | 0.88 (0.53–1.46) | 1.01 (0.71–1.44) | 0.97 (0.65–1.46) | ||
IGF-1 (nmol/L) | ||||||
< 18.3 | 3 | Reference | Reference | 12 | Reference | Reference |
18.3–23.2 | 11 | 4.61 (1.26–16.96) | 4.98 (1.33–18.65) | 13 | 1.38 (0.61–3.15) | 1.37 (0.60–3.13) |
> 23.2 | 9 | 4.68 (1.19–18.46) | 5.13 (1.26–20.88) | 10 | 1.61 (0.67–3.88) | 1.64 (0.68–3.95) |
P trend | 0.05 | 0.04 | 0.54 | 0.54 | ||
Per 1-SD increase | 1.73 (1.07–2.79) | 1.76 (1.08–2.88) | 1.11 (0.78–1.57) | 1.11 (0.78–1.58) | ||
SHBG (nmol/L) | ||||||
< 45.4 | 8 | Reference | Reference | 13 | Reference | Reference |
45.4–69.0 | 3 | 0.41 (0.11–1.53) | 0.40 (0.10–1.57) | 10 | 0.86 (0.37–1.99) | 0.85 (0.35–2.03) |
> 69.0 | 8 | 0.86 (0.29–2.51) | 0.82 (0.25–2.76) | 10 | 0.80 (0.34–1.92) | 0.79 (0.30–2.06) |
P trend | 0.41 | 0.42 | 0.88 | 0.88 | ||
Per 1-SD increase | 0.75 (0.46–1.21) | 0.69 (0.40–1.17) | 0.89 (0.63–1.26) | 0.88 (0.60–1.29) | ||
Testosterone (nmol/L) | ||||||
< 0.8 | 10 | Reference | Reference | 9 | Reference | Reference |
0.8–1.2 | 6 | 0.66 (0.23–1.90) | 0.66 (0.23–1.92) | 9 | 1.43 (0.53–3.86) | 1.45 (0.54–3.90) |
> 1.2 | 5 | 0.55 (0.18–1.68) | 0.52 (0.17–1.63) | 7 | 1.23 (0.43–3.53) | 1.25 (0.43–3.60) |
P trend | 0.53 | 0.50 | 0.78 | 0.77 | ||
Per 1-SD increase | 0.75 (0.47–1.18) | 0.74 (0.47–1.17) | 1.26 (0.85–1.89) | 1.27 (0.85–1.90) | ||
Free testosterone (pmol/L) | ||||||
< 9.6 | 9 | Reference | Reference | 4 | Reference | Reference |
9.6–15.8 | 5 | 0.56 (0.18–1.76) | 0.60 (0.19–1.93) | 13 | 4.33 (1.22–15.38) | 4.58 (1.28–16.44) |
> 15.8 | 4 | 0.44 (0.13–1.51) | 0.42 (0.11–1.56) | 7 | 2.57 (0.66–10.00) | 2.95 (0.73–11.97) |
P trend | 0.37 | 0.40 | 0.07 | 0.06 | ||
Per 1-SD increase | 0.81 (0.50–1.32) | 0.80 (0.48–1.34) | 1.37 (0.90–2.08) | 1.47 (0.95–2.28) |